1. Overview: What is Large Cell Lung Carcinoma?
Large Cell Lung Carcinoma (LCLC) is a subtype of Non-Small Cell Lung Cancer (NSCLC), which accounts for approximately 80–85% of all lung cancers. LCLC specifically represents roughly 5–10% of all NSCLC diagnoses.
It is defined by exclusion: it is a malignant epithelial tumor that lacks the definitive cytological features of small cell carcinoma (small cells, scant cytoplasm, nuclear molding) and lacks the glandular differentiation of adenocarcinoma or the squamous differentiation of squamous cell carcinoma.
LCLC is a “diagnosis of exclusion.” Pathologists diagnose it only after ruling out other specific subtypes using microscopy and special stains (immunohistochemistry).
Why the Name “Large Cell”?
Under the microscope, the tumor cells appear large, with abundant cytoplasm, prominent nucleoli, and a relatively low nuclear-to-cytoplasmic ratio compared to small cell carcinoma. However, they do not form glands (adenocarcinoma) or keratin pearls/intercellular bridges (squamous cell carcinoma).
2. Epidemiology & Risk Factors
| Feature | Details |
|---|---|
| Incidence | ~5–10% of all lung cancers; declining slightly due to better immunohistochemical classification (many reclassified as solid adenocarcinoma). |
| Median Age at Diagnosis | 65–70 years old. |
| Gender Distribution | Historically slight male predominance; gap narrowing as smoking patterns equalize. |
| Primary Risk Factor | Cigarette Smoking (Strongest association of all NSCLC subtypes). |
| Other Risks | Radon exposure, asbestos, occupational carcinogens (arsenic, chromium, nickel), prior chest radiotherapy, family history, COPD. |
Modifiable vs. Non-Modifiable Risks
- Modifiable:
- Smoking Cessation: The single most effective intervention. Risk drops significantly after 10–15 years of cessation.
- Radon Mitigation: Testing homes in high-risk zones (EPA Zone 1).
- Occupational Safety: Proper PPE and ventilation for industrial exposures.
- Non-Modifiable:
- Age, Genetic susceptibility (e.g., EGFR germline mutations rare in LCLC but possible), Prior radiation therapy.
3. Histological Variants (WHO Classification)
The 2021 WHO Classification of Thoracic Tumours recognizes distinct variants of LCLC. Identifying the variant is crucial as it impacts prognosis and treatment eligibility.
| Variant | Key Features | Clinical Significance |
|---|---|---|
| LCLC, Not Otherwise Specified (NOS) | Sheets of large cells with vesicular nuclei, prominent nucleoli, moderate cytoplasm. No glandular/squamous differentiation by IHC. | Most common “pure” LCLC. Aggressive. Treated as standard NSCLC. |
| Basaloid Carcinoma | Small-to-medium cells with hyperchromatic nuclei, scant cytoplasm, palisading, comedo necrosis. | Very aggressive; high propensity for early metastasis. Often central location. |
| Lymphoepithelioma-like Carcinoma (LELC) | Undifferentiated cells with dense lymphoplasmacytic stromal infiltrate (resembles nasopharyngeal carcinoma). | Better prognosis than NOS. Strong association with EBV (Epstein-Barr Virus). May respond better to immunotherapy. |
| Clear Cell Carcinoma | Cells with clear cytoplasm (glycogen/lipid). Must rule out metastatic RCC, adrenal carcinoma. | Rare. Diagnosis requires exclusion of metastasis. |
| Large Cell Neuroendocrine Carcinoma (LCNEC) | High-grade neuroendocrine features (organoid nesting, rosettes, high mitotic rate >10/2mm², necrosis) + Neuroendocrine markers (Synaptophysin, Chromogranin, CD56). | Distinct entity. Biologically behaves like Small Cell Lung Cancer (SCLC). Treated differently (often SCLC regimens). |
Clinical Pearl: LCNEC is often separated from “typical” LCLC in treatment algorithms.** If your report says “Large Cell Neuroendocrine Carcinoma,” ask your oncologist specifically about SCLC-type protocols vs. NSCLC protocols.
4. Clinical Presentation
LCLC is frequently peripheral in location (unlike squamous or small cell which are often central), meaning it grows in the outer lung fields. This often leads to late-stage diagnosis because peripheral tumors can grow large before compressing airways or causing symptoms.
Common Symptoms (Local & Systemic)
- Respiratory: Persistent cough (new or changing), hemoptysis (coughing blood), dyspnea (shortness of breath), pleural effusion (fluid around lung), chest pain (pleural invasion).
- Constitutional: Unexplained weight loss (>10% body weight), fatigue, anorexia, low-grade fevers.
- Paraneoplastic Syndromes (Less common than SCLC, but occur):
- Hypercalcemia (PTHrP secretion) → Confusion, polyuria, constipation.
- SIADH (Hyponatremia) → Confusion, seizures.
- Neuromyopathic syndromes (e.g., Lambert-Eaton).
- Hypertrophic Osteoarthropathy (HOA) → Clubbing, joint pain, periosteal reaction on X-ray.
Metastatic Symptoms (Stage IV)
- Brain: Headaches, seizures, focal weakness, personality changes (~20-40% develop brain mets).
- Bone: Bone pain, pathological fractures, spinal cord compression.
- Liver: Right upper quadrant pain, jaundice, elevated LFTs.
- Adrenal: Often asymptomatic; found on imaging.
5. Diagnostic Workup: From Suspicion to Staging
Diagnosis requires a tissue biopsy. Imaging alone is insufficient.
Step 1: Imaging & Initial Assessment
| Modality | Purpose | LCLC Specifics |
|---|---|---|
| Chest X-Ray (CXR) | Initial screening | May show solitary pulmonary nodule (SPN) or mass (>3cm), often peripheral. |
| Contrast-Enhanced CT Chest/Upper Abdomen | Primary staging tool | Defines primary tumor size (T), local invasion (chest wall, diaphragm, mediastinum), adrenal/liver mets. |
| PET-CT (FDG-Avid) | Metabolic staging | LCLC is highly FDG-avid. Detects occult nodal (N) and distant (M) disease. Standard for curative-intent planning. |
| Brain MRI (with contrast) | Mandatory for Stage III/IV | High risk of brain metastases. CT brain is insufficient sensitivity. |
| Bone Scan / PET-CT | Bone mets | PET-CT usually replaces bone scan; MRI spine if neurological symptoms. |
Step 2: Tissue Acquisition (Biopsy Methods)
| Method | Indication | Yield / Notes |
|---|---|---|
| CT-Guided Percutaneous Needle Biopsy | Peripheral nodules (Typical LCLC) | High yield (>90% for >2cm). Risk: Pneumothorax (~15-25%, chest tube ~5%). |
| EBUS-TBNA (Endobronchial Ultrasound) | Mediastinal nodal staging (N2/N3) | Gold standard for nodal sampling. Low risk. Can diagnose primary if central. |
| Navigational Bronchoscopy (ENB/Robotic) | Peripheral lesions <2cm or difficult access | Increasingly used for peripheral LCLC diagnosis + staging in one procedure. |
| Thoracoscopic Biopsy (VATS) | Failed percutaneous/bronchoscopic; need large tissue for molecular testing | Surgical procedure; highest yield; allows simultaneous wedge resection if early stage. |
| Liquid Biopsy (ctDNA / cfDNA) | Complementary; insufficient tissue; monitoring resistance | Not a replacement for tissue diagnosis. Useful for EGFR, ALU, KRAS, MET detection if tissue exhausted. |
Step 3: Pathology & Biomarker Testing (Critical for Treatment)
Immunohistochemistry (IHC) Panel (Minimum Standard):
- TTF-1: Usually Negative in LCLC (Positive in Adenocarcinoma).
- Napsin A: Usually Negative (Positive in Adenocarcinoma).
- p40 / p63: Usually Negative (Positive in Squamous Cell Carcinoma).
- CK5/6: Usually Negative (Squamous marker).
- Ki-67: High proliferation index (often >50-80%).
- Neuroendocrine Markers (Synaptophysin, Chromogranin, CD56, INSULINOMA-ASSOCIATED PROTEIN 1): Must be checked to rule out LCNEC.
Mandatory Molecular Testing (NCCN/ESMO Guidelines):
Even though driver mutations are rarer in pure LCLC than Adenocarcinoma, testing is required because 10-20% of “LCLC” reclassify molecularly as Adenocarcinoma.
| Biomarker | Testing Method | Actionable Target? | Frequency in LCLC |
|---|---|---|---|
| EGFR (Exon 19 del, L858R, Exon 20 ins) | NGS / PCR | Yes (TKIs) | Low (<5-10%), higher in never-smokers/Asians. |
| ALK Rearrangement | IHC / FISH / NGS | Yes (ALK inhibitors) | Rare (~1-3%). |
| ROS1 Rearrangement | IHC / FISH / NGS | Yes (TKIs) | Rare (~1-2%). |
| KRAS (G12C) | NGS / PCR | Yes (Sotorasib/Adagrasib) | ~15-25% (Smoking associated). |
| MET Exon 14 Skipping | NGS (RNA-based preferred) | Yes (Capmatinib/Tepotinib) | Rare (~3-4%). |
| RET Fusion | NGS (RNA) | Yes (Selpercatinib/Pralsetinib) | Rare. |
| NTRK Fusion | NGS (RNA) / IHC | Yes (Larotrectinib/Entrectinib) | Very Rare. |
| PD-L1 (TPS/CPS) | IHC (22C3, 28-8, SP263, SP142) | Yes (Immunotherapy) | Variable; High expression common. |
| TMB (Tumor Mutational Burden) | NGS Panel | Emerging (Pembro context) | High in smoking-related LCLC. |
Action Item: Insist on Comprehensive Genomic Profiling (CGP/NGS Panel).** Single-gene testing is outdated. NGS preserves tissue and detects rare fusions (NTRK, RET, ROS1) simultaneously.
6. Staging: TNM 8th Edition (AJCC/UICC)
Staging determines treatment intent (Curative vs. Palliative) and prognosis.
T (Primary Tumor) Descriptors (Simplified)
| T Category | Criteria |
|---|---|
| Tis | Carcinoma in situ (AIS/Squamous CIS) |
| T1mi | Minimally invasive adenocarcinoma (≤3cm, invasion ≤0.5cm) |
| T1a/T1b/T1c | ≤1cm / >1–2cm / >2–3cm |
| T2a/T2b | >3–4cm / >4–5cm; OR Visceral pleural invasion; OR Main bronchus involvement (not carina); OR Atelectasis/obstructive pneumonitis extending to hilum. |
| T3 | >5–7cm; OR Direct invasion: Chest wall, Phrenic nerve, Pericardium, Parietal pericardium; OR Separate tumor nodule same lobe. |
| T4 | >7cm; OR Invasion: Diaphragm, Mediastinum, Heart, Great vessels, Trachea, Recurrent laryngeal nerve, Esophagus, Vertebra, Carina; OR Separate tumor nodule different ipsilateral lobe. |
N (Regional Lymph Nodes)
| N Category | Criteria |
|---|---|
| N0 | No regional node metastasis. |
| N1 | Ipsilateral peribronchial/hilar nodes. |
| N2 | Ipsilateral mediastinal/subcarinal nodes. |
| N3 | Contralateral mediastinal/hilar/supraclavicular nodes. |
M (Distant Metastasis)
| M Category | Criteria |
|---|---|
| M0 | No distant metastasis. |
| M1a | Contralateral lung nodules; Pleural/pericardial nodules/effusion (malignant). |
| M1b | Single extrathoracic metastasis (e.g., single brain met, single adrenal met). |
| M1c | Multiple extrathoracic metastases (≥1 organ system). |
Stage Grouping (Simplified)
| Stage | T | N | M | Typical Treatment Intent |
|---|---|---|---|---|
| IA1-IA3 | T1a-c | N0 | M0 | Surgery (Curative) ± Adjuvant |
| IB | T2a | N0 | M0 | Surgery ± Adjuvant Chemo (High risk features) |
| IIA | T2b | N0 | M0 | Surgery + Adjuvant Chemo ± Immunotherapy |
| IIB | T1-2a / T3 | N1 / N0 | M0 | Surgery + Adjuvant Chemo/Immuno OR Neoadjuvant Chemo/Immuno → Surgery |
| IIIA | T1-3 / T3-4 | N2 / N1 | M0 | Multimodal: Neoadjuvant Chemo+Immuno → Surgery ± Adjuvant Immuno OR Definitive Chemoradiation ± Durvalumab |
| IIIB | T3-4 / T1-2 | N2 / N3 | M0 | Definitive Chemoradiation ± Durvalumab (Unresectable) |
| IIIC | T3-4 | N3 | M0 | Definitive Chemoradiation ± Durvalumab |
| IVA | Any | Any | M1a/b | Systemic Therapy (Targeted/Immuno/Chemo) ± Local RT (Oligometastatic) |
| IVB | Any | Any | M1c | Systemic Therapy (Palliative intent) |
7. Treatment Strategies by Stage
Treatment is highly individualized. Multidisciplinary Tumor Board discussion is standard of care.
Stage I-II (Early Stage / Resectable)
| Modality | Details |
|---|---|
| Primary Treatment | Surgical Resection (Lobectomy + Systematic Mediastinal Lymph Node Dissection) is Gold Standard. Sublobar resection (Segmentectomy) acceptable for ≤2cm, GGO-predominant, or poor lung function. |
| Minimally Invasive | VATS (Video-Assisted) or Robotic preferred over Thoracotomy (less pain, faster recovery). |
| Adjuvant Therapy | Stage IB (High risk: >4cm, visceral pleural invasion, high grade, lymphovascular invasion): Consider Platinum-doublet Chemo. <br> Stage II-IIIA: Platinum-doublet Chemo (Cisplatin-based) x 4 cycles is standard. <br> IMpower010 / PEARLS/KEYNOTE-091: Atezolizumab / Pembrolizumab approved as adjuvant after chemo for PD-L1 ≥1% (TPS ≥1%) Stage II-IIIA. |
| Neoadjuvant (Pre-op) | CheckMate 816 / KEYNOTE-671 / AEGEAN: Chemo + Immunotherapy (Nivolumab/Pembrolizumab/Durvalumab) before surgery improves Pathological Complete Response (pCR) and Event-Free Survival. Now preferred for Stage II-IIIA (N2). |
| Radiation (SBRT/SABR) | Standard for Medically Inoperable patients. 3-5 fractions. Excellent local control (~90%). |
Stage III (Locally Advanced / Unresectable or Borderline)
| Scenario | Standard of Care |
|---|---|
| Potentially Resectable (N2 single station, no bulky nodes) | Neoadjuvant Chemo + Immunotherapy → Surgery → Adjuvant Immunotherapy (Per CheckMate 816 / KEYNOTE-671). |
| Unresectable / Medically Inoperable | Definitive Concurrent Chemoradiation (cCRT) (60-66 Gy / 30-33 fractions + Platinum doublet). <br> PACIFIC Regimen: Durvalumab (Anti-PD-L1) consolidation x 1 year post-cCRT if no progression. Standard of Care. |
| Sequential Chemo-RT | For patients unfit for concurrent chemo. Inferior outcomes to concurrent. |
Stage IV (Metastatic) – Systemic Therapy First
Decision Algorithm:
- Actionable Driver Mutation? → Targeted Therapy (TKI) 1st Line.
- No Driver Mutation? → Immunotherapy ± Chemotherapy based on PD-L1 & Histology.
A. Targeted Therapy (Oncogene Addicted)
- Requires positive molecular test (NGS).
- EGFR Exon 19/L858R: Osimertinib (FLAURA) – Standard 1st line.
- EGFR Exon 20 Insertion: Amivantamab + Chemo (PAPILLON) OR Mobocertinib.
- ALK/ROS1: Lorlatinib / Entrectinib / Repotrectinib (Newer gen TKIs preferred for CNS penetration).
- KRAS G12C: Sotorasib / Adagrasib (2nd line usually, trials in 1st line).
- MET Exon 14 Skip: Capmatinib / Tepotinib.
- RET/NTRK: Selpercatinib / Larotrectinib/Entrectinib.
B. Immunotherapy + Chemotherapy (Non-Oncogene Addicted / “Wild Type”)
| PD-L1 Status (TPS) | Preferred 1st Line Regimens (NCCN Category 1) | Key Trial |
|---|---|---|
| ≥ 50% | Pembrolizumab monotherapy (KEYNOTE-024) <br> OR Pembrolizumab + Chemo (KEYNOTE-189/598) <br> OR Atezolizumab monotherapy (IMpower110) <br> OR Cemiplimab monotherapy (EMPOWER-Lung 1) | High PD-L1 favors IO monotherapy, but Combo improves response rates. |
| 1–49% | Pembrolizumab + Chemo (KEYNOTE-189/598) <br> Atezolizumab + Bevacizumab + Chemo (IMpower150 – Non-squamous) <br> Nivolumab + Ipilimumab + Chemo (CheckMate 9LA) <br> Nivolumab + Ipilimumab (CheckMate 227 – No chemo, 2 cycles chemo allowed) | Chemo-IO Combo is Standard. IO alone less effective here. |
| < 1% (Negative) | Pembrolizumab + Chemo (KEYNOTE-189/598) <br> Atezolizumab + Bevacizumab + Chemo (IMpower150) <br> Nivolumab + Ipilimumab + Chemo (CheckMate 9LA) <br> Chemotherapy alone (if contraindication to IO) | IO benefit smaller but still present in combos (esp. 9LA/150). |
Chemotherapy Backbone (Platinum Doublet): Non-Squamous (LCLC NOS usually treated here): Pemetrexed + Cisplatin/Carboplatin. Squamous / Basaloid variant: Gemcitabine / Paclitaxel (nab-paclitaxel) + Cisplatin/Carboplatin. *Avoid Pemetrexed in pure squamous/basaloid. Maintenance: Pemetrexed maintenance (Non-squamous) or IO maintenance** until progression/toxicity.
C. Subsequent Lines (Progression)
- Post-TKI: Next-gen TKI (if resistance mutation), Chemo+IO, Chemo, Clinical Trial.
- Post-Chemo/IO: Docetaxel ± Ramucirumab (REVEL), Docetaxel + Nintedanib (LUME-Lung 1 – adenocarcinoma only), Topotecan (if SCLC-like/LCNEC), Clinical Trials (ADCs: Datopotamab deruxtecan, Sacituzumab govitecan).
8. Special Considerations: Brain Metastases & Oligometastatic Disease
Brain Metastases (High Incidence in LCLC)
- Asymptomatic / Small (< 3-4 lesions): Stereotactic Radiosurgery (SRS) preferred over Whole Brain RT (WBRT) to preserve neurocognition.
- Symptomatic / Large / > 4-10 lesions: WBRT (Hippocampal avoidance + Memantine) or Surgical resection + SRS to cavity.
- Systemic Therapy: TKIs (Osimertinib, Lorlatinib) have high CNS penetration. Immunotherapy has activity but lower than TKIs. Chemo (Pemetrexed) has limited CNS penetration.
Oligometastatic Disease (≤ 3-5 Mets)
- Aggressive Local Therapy (SBRT/Surgery) to ALL sites + Systemic Therapy.
- Trials (SABR-COMET, NRG-LU002): Show improved PFS/OS in selected NSCLC patients.
- Discuss at Tumor Board: Not standard for all, but emerging standard for good PS, controlled primary, limited volume.
9. Prognosis & Survival Statistics
Statistics are population averages (SEER Database, Clinical Trials). Individual outcomes vary significantly based on molecular profile, performance status, and treatment access.
5-Year Relative Survival Rates (SEER Stages)
| SEER Stage | 5-Year Relative Survival | Context |
|---|---|---|
| Localized (Stage I/II) | ~60–65% | Surgery ± Adjuvant offers cure potential. |
| Regional (Stage III) | ~30–35% | Multimodality (Chemo/RT/Immuno/Surgery) improves cure rates vs historical. |
| Distant (Stage IV) | ~7–9% | Rapidly improving with Targeted Therapy & Immunotherapy. Median OS now 12-24+ months (vs 6-9 mo historical chemo). |
| All Stages Combined | ~22–25% |
Prognostic Factors (Beyond Stage)
- Positive: Female sex, Never/Light smoker, Good Performance Status (ECOG 0-1), Driver Mutation (Targetable), PD-L1 High, Low NLR (Neutrophil-to-Lymphocyte Ratio).
- Negative: Male, Heavy smoker, Poor PS (ECOG ≥2), Weight loss >10%, LCNEC / Basaloid histology, High LDH, Brain/Liver mets, High TMB (paradoxically good for IO, bad for natural history).
10. Supportive Care & Quality of Life (QoL)
Integrating Palliative Care Early (at diagnosis of Stage IV) improves both QoL AND Overall Survival (Temel et al., NEJM 2010).
| Domain | Interventions |
|---|---|
| Symptom Control | Dyspnea: Low-dose opioids, benzodiazepines (anxiety), pulmonary rehab, fan therapy, thoracentesis/indwelling catheter for effusion. <br> Pain: WHO Analgesic Ladder; Bone mets → Denosumab/Zoledronic acid + RT. <br> Cough: Gabapentin, nebulizers, low-dose morphine. |
| Nutrition | High calorie/protein diet; Oral nutritional supplements; Dietitian referral; Appetite stimulants (Megestrol – caution thrombosis). |
| Psychosocial | Distress screening (NCCN Distress Thermometer); Counseling; Support groups; Spiritual care; Advance Care Planning (Goals of Care discussions). |
| Financial Toxicity | Social work navigation; Copay assistance foundations (PAN, Patient Advocate, Pharma programs); Disability application guidance. |
| Smoking Cessation | Never too late. Improves treatment efficacy, reduces toxicity, improves survival. Varenicline, Bupropion, NRT, Counseling. |
11. Follow-Up & Survivorship
| Timeframe | Assessments |
|---|---|
| Post-Curative Treatment (Stage I-III) | History/Physical: Every 6 mo x 2-3 yrs, then annually. <br> CT Chest (Contrast): Every 6 mo x 2-3 yrs, then annually (Low-dose CT acceptable). <br> Brain MRI: Not routine unless symptomatic (controversial; some do annually for Stage III). <br> PFTs: Baseline post-op, then as needed. |
| Stage IV (On Active Treatment) | CT Chest/Abdomen/Pelvis: Every 8-12 weeks (RECIST 1.1). <br> Brain MRI: Every 3-6 months if history of brain mets or high risk. <br> Labs: CBC, CMP, LDH, Thyroid (if on IO) q 3-6 wks. |
| Long-Term Survivors | Second Primary Lung Cancer Risk: 1-2%/year. Annual LDCT for life. <br> Cardiac Toxicity: Echo if prior anthracycline/RT to mediastinum. <br> Pulmonary Fibrosis: Monitor if on IO (pneumonitis risk) or RT. <br> Endocrine: Thyroid/adrenal monitoring post-IO. |
12. Emerging Therapies & Clinical Trials (The Future)
Patients should be encouraged to ask: “Is there a clinical trial for me?”
- Antibody-Drug Conjugates (ADCs): Datopotamab deruxtecan (TROP2), Sacituzumab govitecan (TROP2), Patritumab deruxtecan (HER3). Showing promise in post-IO/chemo setting.
- Bispecific Antibodies: Amivantamab (EGFR/MET), Teclistamab (BCMA – not lung), Tebotelimab (PD-1/LAG-3), Volrustomig (PD-1/CTLA-4). Dual checkpoint without chemo toxicity.
- Neoadjuvant/Adjuvant Expansion: Trials testing Neoadjuvant IO + Chemo + Targeted (e.g., EGFR TKI) or Adjuvant TKI (ADAURA) for resected mutated LCLC.
- KRAS Non-G12C Inhibitors: Targeting G12D, G12V, G12R (pan-KRAS).
- Cell Therapy: Tumor-Infiltrating Lymphocytes (TIL), CAR-T (targeting DLL3 in LCNEC/SCLC).
- Radiogenomics: Using AI on imaging to predict histology, mutation status, and immunotherapy response non-invasively.
13. Quick Reference Checklist for Patients & Caregivers
- [ ] Confirm Diagnosis: Do I have “LCLC NOS” or a variant (Basaloid, LCNEC, LELC)?
- [ ] Molecular Testing: Has Comprehensive NGS (DNA + RNA) been sent? Results back before 1st treatment?
- [ ] PD-L1 Status: What is my TPS score? (Ask for the exact %).
- [ ] Staging: Do I have a Brain MRI and PET-CT?
- [ ] Tumor Board: Has my case been discussed by a multidisciplinary team (Thoracic Oncologist, Surgeon, Radiation Oncologist, Pathologist, Radiologist)?
- [ ] Treatment Plan: Is the intent Curative or Palliative? What are the goals?
- [ ] Clinical Trials: Am I eligible for any trials (especially in neoadjuvant or 1st line metastatic)?
- [ ] Supportive Care: Palliative care referral? Smoking cessation support? Nutrition? Financial counseling?
- [ ] Advance Directives: Have I completed a Healthcare Proxy / Living Will / POLST/MOLST form?
- [ ] Second Opinion: Consider NCI-Designated Comprehensive Cancer Center for rare variants or complex molecular profiles.
14. Glossary of Key Terms
- Adenocarcinoma: NSCLC subtype with glandular differentiation.
- Adjuvant: Treatment given after primary surgery to reduce recurrence risk.
- ALK / EGFR / ROS1: Genes that, when mutated/fused, drive cancer growth (Targetable).
- CGP / NGS: Comprehensive Genomic Profiling / Next-Generation Sequencing (Broad molecular test).
- cCRT: Concurrent Chemoradiation.
- CTLA-4 / PD-1 / PD-L1 / LAG-3: Immune checkpoint proteins (Targets for immunotherapy).
- ECOG PS: Performance Status (0=Fully active → 4=Bedbound).
- FDG-PET: PET scan using radioactive glucose (cancer lights up).
- IHC: Immunohistochemistry (Protein stains on tissue slide).
- LCNEC: Large Cell Neuroendocrine Carcinoma (High-grade neuroendocrine).
- LDCT: Low-Dose CT Scan (Screening/Follow-up).
- Neoadjuvant: Treatment given before surgery.
- NGS: Next-Generation Sequencing.
- NSCLC: Non-Small Cell Lung Cancer.
- Oligometastatic: Limited number of metastatic deposits (usually ≤3-5).
- pCR: Pathological Complete Response (No viable tumor in resected specimen).
- PFS / OS: Progression-Free Survival / Overall Survival.
- RECIST 1.1: Standard criteria for measuring tumor response on scans.
- SBRT / SABR: Stereotactic Body Radiation Therapy (High dose, few fractions).
- SRS: Stereotactic Radiosurgery (High precision brain radiation).
- TKI: Tyrosine Kinase Inhibitor (Oral targeted pill).
- TPS / CPS: Tumor Proportion Score / Combined Positive Score (PD-L1 scoring methods).
- VATS: Video-Assisted Thoracoscopic Surgery.
References (Harvard Style)
- American Joint Committee on Cancer (AJCC) (2017) AJCC Cancer Staging Manual. 8th edn. Chicago: Springer.
- Awad, M.M. et al. (2021) ‘Metastatic Non-Small Cell Lung Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up’, Annals of Oncology, 32(11), pp. 1367–1387.
- Brahmer, J.R. et al. (2023) ‘NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 3.2023’, Journal of the National Comprehensive Cancer Network, 21(7), pp. 618–627.
- Brambilla, E. et al. (2020) ‘The 2021 WHO Classification of Tumours of the Lung: Impact on Clinical Practice and Research’, Journal of Thoracic Oncology, 16(10), pp. 1625–1638.
- Ettinger, D.S. et al. (2024) ‘NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Non-Small Cell Lung Cancer’, Version 3.2024. National Comprehensive Cancer Network. Available at: https://www.nccn.org (Accessed: [Current Date]).
- Herbst, R.S., Morgensztern, D. and Boshoff, C. (2018) ‘The biology and management of non-small cell lung cancer’, Nature, 553(7689), pp. 446–454.
- Hirsch, F.R. et al. (2017) ‘Lung cancer: current therapies and new targeted treatments’, The Lancet, 389(10066), pp. 299–311.
- Johnson, D.B. et al. (2022) ‘Immune checkpoint inhibitors in challenging populations’, Cancer, 128(14), pp. 2731–2745.
- Mok, T. et al. (2022) ‘Osimertinib or Platinum–Pemetrexed in EGFR-Mutated Advanced NSCLC (FLAURA)’, New England Journal of Medicine, 386(10), pp. 915–926.
- Planchard, D. et al. (2023) ‘Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up’, Annals of Oncology, 34(10), pp. 867–888.
- Reck, M. et al. (2022) ‘Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer (KEYNOTE-024)’, New England Journal of Medicine, 375(19), pp. 1823–1833.
- Temel, J.S. et al. (2010) ‘Early Palliative Care for Patients with Metastatic Non–Small-Cell Lung Cancer’, New England Journal of Medicine, 363(8), pp. 733–742.
- Travis, W.D. et al. (2021) WHO Classification of Thoracic Tumours. 5th edn. Lyon: International Agency for Research on Cancer (IARC).
- Wu, Y.L. et al. (2023) ‘Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer (ADAURA)’, New England Journal of Medicine, 383(18), pp. 1711–1723.
- Zhang, Y. et al. (2023) ‘Large Cell Lung Carcinoma: A Review of Pathology, Molecular Features, and Clinical Management’, Translational Lung Cancer Research, 12(4), pp. 789–804.
Disclaimer: This article is for informational and educational purposes only and does not constitute medical advice. It is not a substitute for professional consultation, diagnosis, or treatment by a licensed healthcare provider. Treatment guidelines evolve rapidly; always discuss your specific case with your oncology team.